Celularity Inc (CELU) stock
CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.57−0.05 (-7.75%)
Close on Nov 17, 2026Market cap $18.53MP/E –Yield –
Celularity operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Celularity's operating income for the twelve months ending Jun 30, 2026 was -$49.33M. For fiscal 2025 it was -$61.31M. The highest annual figure on record is -$1.68M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$61.31M | – |
| FY2024 | Dec 31, 2024 | -$38.36M | – |
| FY2023 | Dec 31, 2023 | -$192.29M | – |
| FY2022 | Dec 31, 2022 | -$25.60M | – |
| FY2021 | Dec 31, 2021 | -$109.06M | – |
| FY2020 | Dec 31, 2020 | -$151.93M | – |
| FY2019 | Dec 31, 2019 | -$1.68M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.24M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.13M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.06M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.90M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.86M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.49M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.28M | -169.7% |
| Q3 FY2024 | Sep 30, 2024 | -$11.53M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.18M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.38M | – |
| Q4 FY2023 | Dec 31, 2023 | $13.32M | -23.8% |
| Q3 FY2023 | Sep 30, 2023 | -$99.26M | – |
| Q2 FY2023 | Jun 30, 2023 | -$42.48M | -1117.4% |
| Q1 FY2023 | Mar 31, 2023 | -$63.87M | – |
| Q4 FY2022 | Dec 31, 2022 | $17.49M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.65M | -151.8% |
| Q2 FY2022 | Jun 30, 2022 | $4.18M | – |
| Q1 FY2022 | Mar 31, 2022 | -$41.61M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.95M | -235.2% |
| Q3 FY2021 | Sep 30, 2021 | $10.90M | – |
| Q2 FY2021 | Jun 30, 2021 | -$60.61M | – |
| Q1 FY2021 | Mar 31, 2021 | -$44.40M | – |
| Q4 FY2020 | Dec 31, 2020 | $11.06M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.81M | – |
| Q2 FY2020 | Jun 30, 2020 | -$208.23K | – |
| Q1 FY2020 | Mar 31, 2020 | -$241.64K | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.37M | – |
| Q3 FY2019 | Sep 30, 2019 | -$202.00K | – |
| Q2 FY2019 | Jun 30, 2019 | -$115.25K | – |
| Q1 FY2019 | Mar 31, 2019 | -$121 | – |
See a number that looks wrong?